Evidence map›Paper›PMID 32258535›Full record

ReviewTranslational gastroenterology and hepatology2020

Non-invasive diagnosis: non-alcoholic fatty liver disease and alcoholic liver disease.

Jose Altamirano, Qiaochu Qi, Sabina Choudhry, Mohamed Abdallah, Ashwani K Singal, Abhinav Humar, Ramón Bataller, Amir Ali Borhani, Andrés Duarte-Rojo

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational gastroenterology and hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. The Link between NAFLD and Metabolic Syndrome.Diagnostics (Basel, Switzerland) · 2023
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jose AltamiranoDepartment of Internal Medicine (Hepatology Section), Hospital Quironsalud Barcelona, Spain.
Qiaochu QiDepartment of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Sabina ChoudhryDepartment of Radiology, University of South Dakota, Vermillion, SD, USA.
Mohamed AbdallahDepartment of Internal Medicine (Hepatology Section), University of South Dakota, Vermillion, SD, USA.
Ashwani K SingalDepartment of Medicine, University of South Dakota Sanford School of Medicine, Avera McKennan University Hospital Transplant Hepatology, Sioux Falls, SD, USA.
Abhinav HumarStarzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Ramón BatallerStarzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Amir Ali BorhaniDepartment of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.
Andrés Duarte-RojoStarzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, USA.
University of Pittsburgh · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) are becoming the leading causes of chronic liver disease worldwide, significantly impacting public health and healthcare cost. The development of fibrosis is the main factor leading to early mortality and morbidity in NAFLD and ALD. Thus, it is important to timely and reliably evaluate these diseases at early stages, when fibrosis is not advanced or when steatosis predominates. Liver biopsy has been the standard of reference for fibrosis and steatosis, however, its invasiveness precludes its widespread use. There is growing research on non-invasive methods for diagnosing and stratifying fibrosis and steatosis in NAFLD and ALD. This review presents clinical evidence on the use of non-invasive assessment of liver disease (blood-based and imaging-based) in patients with NALFD and ALD, and proposes algorithms incorporating these tests into their management.

Indexed as

alcoholic liver disease (ALD)fibrosisnon-alcoholic fatty liver disease (NAFLD)Non-invasive diagnosissteatosis

Identifiers

PMID32258535
PMCPMC7063491
OpenAlexW2996875369

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.